The goal of this clinical trial is to learn about treatment for a type of brain cancer called glioma. This clinical trial is for people with glioma who have been cancer-free for a period of time but their cancer has come back. The primary goals of this clinical trial are the following:
* To determine the recommended dose of PCI-24781/Abexinostat with metronomic temozolomide
* To evaluate side effects associated with using PCI-24781/Abexinostat with metronomic temozolomide

开始日期2023-06-26

申办/合作机构

University of Nebraska

[+1]

CTR20191596 / Recruiting临床2期

对甲苯磺酸艾贝司他片单药治疗复发或难治的滤泡性淋巴瘤患者的开放性、单臂、多中心、II期临床研究

主要目的：评估艾贝司他（abexinostat）治疗复发/难治性滤泡性淋巴瘤(FL)患者的客观缓解率（ORR）。次要目的：评估艾贝司他（abexinostat）治疗复发/难治性滤泡性淋巴瘤(FL)患者的缓解持续时间（DOR）；无进展生存期（PFS）；最佳总疗效（BOR）；总生期（OS）；安全性和耐受性。

开始日期2020-06-17

申办/合作机构

百时益医药研发（北京）有限公司

100 项与艾贝司他相关的临床结果

登录后查看更多信息

100 项与艾贝司他相关的转化医学

登录后查看更多信息

100 项与艾贝司他相关的专利（医药）

登录后查看更多信息

项与艾贝司他相关的文献（医药）

2024-11-01·JCO Precision Oncology

Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies

Article

作者: Pawlowska, Nela ; Bergsland, Emily K. ; Munster, Pamela N. ; Thomas, Scott ; Grabowsky, Jennifer ; Dhawan, Mallika S. ; Calabrese, Susan ; Chaudhuri, Sibapriya ; Rozie, Alexandrine ; Aggarwal, Rahul R. ; Tsang, Erica S.

PURPOSEHistone deacetylase (HDAC) inhibition downregulates hypoxia-inducible factor-1α and modulates multiple metabolomic pathways relevant in cancer. Here we report a potential novel biomarker to predict exceptional responders (>3 years) in patients receiving HDAC and vascular endothelial growth factor (VEGF) inhibition.PATIENTS AND METHODSPatients with solid tumor malignancies were enrolled in this phase Ib trial of abexinostat (4/7 ×21 days) and pazopanib (28/28 days), with a dose expansion in renal cell carcinoma (RCC). Plasma was analyzed for metabolomics and peripheral blood mononuclear cells (PBMCs) for VEGF and HDAC2 expression levels.RESULTS Fifty-one patients were enrolled: n = 36 patients in dose escalation and n = 15 in dose expansion. After the initial report in 2017, six patients had remained on study: four with RCC and one each with medullary thyroid and thymic neuroendocrine carcinoma. One patient with RCC remains on treatment for >11 years after progression on five systemic therapies. Overall, the median duration of therapy measured 5.6 (1-133) months. The median duration of therapy in exceptional responders measured 44.1 (39.8-133+) months. The median overall survival in patients with high PBMC HDAC2 expression versus low HDAC2 was 32.3 versus 9.2 months ( P = .004) for all patients and 43.3 versus 25.1 months for patients with RCC ( P = .09). Exceptional responders had lower kynurenine levels both pre- and post-treatment ( P = .002, P < .001, respectively). HDAC2 and kynurenine expression levels were inversely correlated ( P = .02). CONCLUSIONAbexinostat added to pazopanib shows extended tolerability and long-term responses and survival. PBMC HDAC2 levels, the abexinostat target, are relevant predictors of response. In addition, metabolomic assessment points to kynurenine as a predictor for exceptional response to combined VEGF plus HDAC inhibition.

2024-09-20·Leukemia & lymphoma

A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma.

Article

作者: Matasar, Matthew ; Kumar, Anita ; Joseph, Ashlee ; Hamlin, Paul A ; Gurumurthi, Ashwath ; Zelenetz, Andrew D ; von Keudell, Gottfried ; Castro, Ali ; Biggar, Erin ; Bantilan, Kurt S ; Zhu, Menglei ; Salles, Gilles

2024-09-01·Clinical Pharmacology in Drug Development

The Bioequivalence of Abexinostat (CRA‐024781) Tosylate Tablets (20 mg) in Chinese Healthy Subjects Under Fasting Conditions

Article

作者: Guo, Wenqiang ; Tan, Gewen ; Chen, Jian ; Li, Xiang

AbstractThis study aimed to investigate the pharmacokinetic parameters of single oral administration of postchange and prechange abexinostat (CRA‐024781) tosylate tablets in Chinese healthy subjects under fasting conditions, and assess the bioequivalence (BE) of the 2 formulations (Test [T1] and Reference [T2]). This study was a randomized, open‐label, 2‐formulation, fasting administration, single‐dose, 2‐sequence, 2‐cycle, crossover BE study. Thirty‐six subjects were enrolled in the study and 33 subjects completed 2 cycles. The plasma concentrations were determined by liquid chromatography‐tandem mass spectrometry. The 90% confidence intervals (CIs) for the Cmax, AUC0‐t, and AUC0‐∞ of CRA‐024781 and its 2 major metabolites (PCI‐27789 and PCI‐27887, both metabolites are pharmacologically inactive on HDAC1) fell within the acceptable range of 80%‐125%. The results suggest that the CRA‐024781 test preparation (Test [T1]) is bioequivalent to the reference preparation (Reference [T2]) in healthy Chinese subjects under fasting conditions.

项与艾贝司他相关的新闻（医药）

2024-11-08

·医药魔方Info

专利事件| 维得利珠单抗登记专利无效结案，赛立奇单抗首次登记1件序列结构专利

为助力医药行业专利从业者第一时间获取最新专利事件及进展，医药魔方推出了专利事件栏目，将每周对药品相关重要专利事件进行汇总，主要涉及：专利登记/声明、药品专利到期、专利复审与无效、专利PTE/PTA获批等情报。专利情报数据均来源于医药魔方NextPat数据库。本周（2024.10.28-2024.11.03）主要涉及以下内容： 1.中国上市药品专利登记及仿制药专利声明重点内容简介：本周CDE中国上市药品专利信息登记平台新增登记药品专利5件。8月份新获批上市的国产创新药赛立奇单抗注射液首次登记了1件序列结构专利。正大天晴药业将枸橼酸依奉阿克胶囊的晶型专利、富马酸安奈克替尼胶囊的晶型专利新增登记到平台中等。本周2类、3类、4类声明中唯一涉及的生物药是帕妥珠单抗注射液，杭州博之锐生物对帕妥珠单抗的6件登记专利进行了声明，此前已经有齐鲁制药、正大天晴药业提交申报上市，登记专利中的3件此前遭到过齐鲁或正大天晴的无效挑战，1件被宣告部分无效，2件被全部无效。 2.美国FDA桔皮书、紫皮书、美国PTE专利新增重点内容简介：本周FDA桔皮书新增专利数十件，本周FDA桔皮书新增专利数十件，涉及品种Cycloset（溴隐亭）、Caplyta（卢美哌隆）、Orilissa（恶拉戈利）、Artesunate（青蒿琥酯）、Cobenfy（呫诺美林+曲司氯铵）等。 3. 中国药品专利复审、无效情况精选重点内容简介：本周精选的数件药品相关专利有复审决定发文或在驳回后提交了复审请求，涉及达雷妥尤单抗+重组人玻璃酸酶、维拉卡肽、卡格列净等。本周内有1件药品相关专利无效决定发文，烟台蓝纳成生物的临床1期管线177Lu-LNC1003的核心化合物专利被维持专利权有效。维得利珠单抗的一件医药用途专利迎来一份无效宣告案件结案通知书，应是请求人撤回了无效请求。 4. 中国药品专利PTE、PTA情况精选重点内容简介：本周有多件专利权期限补偿审批决定发文，多个药品相关专利获批专利权期限延长，列举了部分本周获批PTA的药品相关专利，涉及lorigerlimab、subasumstat、艾贝司他、dapiglutide等。药品专利事件周报的详细内容请点击阅读原文查看，或者加入文末医药魔方专利信息群获取。医药魔方专利信息群，旨在提供医药行业专利重点事件监控和解读，群内提供以下信息： 1. 及时的医药专利无效信息、复审跟踪、PTE/PTA专利补偿提醒； 2. 中国上市药品专利登记平台最新登记/声明； 3. 桔皮书专利最新登记； 4. 热点医药专利事件解读； 5. 医药专利研究报告； 6. 医药专利相关资讯。目前免费开放中（限前500人）添加左下方微信号，备注“专利-公司-职位"，拉您进群；如想申请NextPat数据库试用，可扫右侧二维码申请试用。

专利无效专利到期

2024-10-16

·徐诺药业官微

印度瑞迪博士实验室国际商务团队访问徐诺药业上海肿瘤临床医学研究中心

中国上海近日，印度知名制药企业瑞迪博士实验室（Dr. Reddy's）国际商务团队一行到访徐诺药业上海肿瘤临床医学研究中心，受到公司董事长兼首席执行官徐英霖先生及其商务团队的热情接待。此次访问旨在探讨双方在全球抗肿瘤药物领域的合作机会。在座谈交流会上，徐诺药业商务团队与瑞迪博士实验室的代表就未来合作的可能性进行了深入探讨。双方一致表示，抗肿瘤药物研发是当前医药领域的重点方向，双方在该领域有着共同的目标和愿景。瑞迪博士实验室作为全球知名的制药企业，在抗肿瘤药物研发领域积累了丰富的经验和资源。徐诺药业则凭借艾贝司他等创新药物的研发实力，展现出了强大的市场竞争力。双方期待在印度和新兴市场如拉丁美洲、南非等国家共同开展艾贝司他的研发与商业化合作。徐诺药业徐英霖先生表示：“我们很高兴有机会与瑞迪博士实验室这样的知名企业进行交流，这将使我们在为肿瘤患者提供更多优质产品方面又向前迈出了一步。我们的目标是在抗肿瘤药物领域建立起强大而全面的产品组合，为全球患者带来福音。” 关于徐诺徐诺药业(南京)有限公司是一家以患者需求为导向专注开发抗肿瘤药物的全球性生物制药公司，在自主研发和License in（授权引进）双引擎驱动下，旨在为全球患者提供更有效的治疗方案。目前的产品管线主要包括三款候选药物，艾贝司他、 XP-105 和 XP-102。公司拥有这些药物的全球独家研发、生产和商业化权益。公司全球总部在南京，分别在上海、美国加州都设有办公室。公司创立团队曾在跨国生物制药公司（先灵、礼来、默克、罗氏、施贵宝等）从事研发、临床、商务等工作。公司联合创始人、董事长、首席执行官兼总裁徐英霖先生是一位成功的连续创业家，曾联合创办了两家美中生物制药公司并成功退出。此外，公司与Pharmacyclics / AbbVie，Boehringer Ingelheim和Janssen等知名跨国药企深度合作。投资者关系、媒体和商务拓展请联系： angela.feng@xynomicpharma.com

引进/卖出

2024-09-19

·PRNewswire

Mantle Cell Lymphoma Clinical Trial Pipeline Insights Featuring 20+ Companies | DelveInsight

Mantle cell lymphoma is a rare and aggressive type of non-Hodgkin lymphoma originating from B-cells in the "mantle zone" of the lymph nodes. The development of novel targeted therapies and immunotherapies, such as Bruton's tyrosine kinase (BTK) inhibitors, is improving treatment outcomes and driving market growth for Mantle cell lymphoma. LAS VEGAS, Sept. 19, 2024 /PRNewswire/ -- DelveInsight's ' Mantle Cell Lymphoma Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline mantle cell lymphoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the mantle cell lymphoma pipeline domain. Key Takeaways from the Mantle Cell Lymphoma Pipeline Report DelveInsight's mantle cell lymphoma pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for mantle cell lymphoma treatment. Key mantle cell lymphoma companies such as AbbVie, Adicet Bio, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Nurix, LegoChem Biosciences, Xynomic Pharmaceuticals, Merck & Co, Incyte Corporation, TG Therapeutics, Janssen/Pharmacyclics, Eternity Bioscience, Traws Pharm, Advenchen Laboratories, and others are evaluating new mantle cell lymphoma drugs to improve the treatment landscape. Promising mantle cell lymphoma pipeline therapies such as Venetoclax, ADI-001, Orelabrutinib, LP-168, BGB-11417, NX 2127, LCB 71, NX 5948, Abexinostat, Pembrolizumab, Parsaclisib, Umbralisib, Ibrutinib, Edralbrutinib, Narazaciclib, Lucitanib, and others are under different phases of mantle cell lymphoma clinical trials. In May 2024, AstraZeneca had announced positive interim results from the Phase III ECHO clinical trial, which evaluated Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) in combination with standard chemoimmunotherapy for treating mantle cell lymphoma (MCL). In March 2024, BeiGene, Ltd. announced the presentation of emerging oncology pipeline data at the American Association for Cancer Research (AACR) Annual Meeting. Additional highlights include preclinical characterization data for an investigational BTK degrader, BGB-16673, currently in clinical development for B-cell malignancies, including mantle cell lymphoma In October 2023, Ascentage Pharma announced that it has entered into a clinical collaboration with AstraZeneca Investment. The two companies will jointly conduct a registrational Phase III study of the Bcl-2 inhibitor, APG-2575 (lisaftoclax), in combination with AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor, CALQUENCE® (acalabrutinib), in treatment-naive patients with first-line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In January 2023, the FDA granted an orphan drug designation to LP-284, a novel small-molecule, next-generation acylfulvene, for the treatment of mantle cell lymphoma (MCL), a rare and aggressive form of B-cell non-Hodgkin lymphoma (NHL), according to an announcement from Lantern Pharma. Request a sample and discover the recent advances in mantle cell lymphoma treatment drugs @ Mantle Cell Lymphoma Pipeline Report The mantle cell lymphoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage mantle cell lymphoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the mantle cell lymphoma clinical trial landscape. Mantle Cell Lymphoma Overview Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphomas (NHLs) characterized by the (11,14) translocation, leading to overexpression of the cyclin D1 (CCND1) gene. Its various morphological variants can make diagnosis challenging, though some cases are straightforward. Many individuals with MCL are asymptomatic in the early stages, but may later seek medical attention due to persistent, typically painless swelling of lymph nodes, especially in the neck and throat region (e.g., Waldeyer's ring). MCL is marked by a reciprocal chromosomal translocation t(11;14)(q13;q32), which places the cyclin D1 gene next to the immunoglobulin heavy chain gene, causing continuous cyclin D1 expression. This overexpression contributes to tumor cell proliferation through cell cycle dysregulation, chromosomal instability, and epigenetic changes. Rarely, MCL cases without this translocation may involve CCND2 or CCND3 translocations. Hypothetical molecular subtypes, based on the cell of origin, correlate with clinical phenotypes: classical or aggressive MCL arises from naive B cells lacking or having limited iGVH mutations and expressing SOX11, a neural transcription factor inhibiting terminal B cell differentiation. The indolent variant originates from antigen-experienced B cells with IGVH somatic hypermutations, typically SOX11-negative and genetically stable. Diagnosis of MCL involves detailed patient history, thorough clinical evaluation, and specialized tests, including biopsy of an affected lymph node or bone marrow. These tests confirm the NHL type and subtype, assess disease extent, and determine appropriate treatments. Treatment for MCL is multifaceted and tailored to each patient, often including chemotherapy, immunotherapy drugs like rituximab, targeted therapies such as ibrutinib, and stem cell transplants, particularly for aggressive disease or younger patients. Radiation therapy may target specific lymphoma areas. Participation in clinical trials can offer new treatment options. Treatment plans are developed collaboratively by healthcare professionals and patients, considering disease stage, overall health, and personal preferences. Regular monitoring and follow-up care are essential to track treatment response and manage side effects effectively. Find out more about mantle cell lymphoma treatment drugs @ Drugs for Mantle Cell Lymphoma Treatment A snapshot of the Mantle Cell Lymphoma Pipeline Drugs mentioned in the report: Learn more about the emerging mantle cell lymphoma pipeline therapies @ Mantle Cell Lymphoma Clinical Trials Mantle Cell Lymphoma Therapeutics Assessment The mantle cell lymphoma pipeline report proffers an integral view of the mantle cell lymphoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Mantle Cell Lymphoma Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action: Apoptosis stimulants, Proto-oncogene protein c-bcl-2 inhibitors, Proteasome inhibitors, Immunologic cytotoxicity, T lymphocyte replacements, Agammaglobulinemia tyrosine kinase inhibitors Key Mantle Cell Lymphoma Companies: AbbVie, Adicet Bio, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Nurix, LegoChem Biosciences, Xynomic Pharmaceuticals, Merck & Co, Incyte Corporation, TG Therapeutics, Janssen/Pharmacyclics, Eternity Bioscience, Traws Pharm, Advenchen Laboratories, and others Key Mantle Cell Lymphoma Pipeline Therapies: Venetoclax, ADI-001, Orelabrutinib, LP-168, BGB-11417, NX 2127, LCB 71, NX 5948, Abexinostat, Pembrolizumab, Parsaclisib, Umbralisib, Ibrutinib, Edralbrutinib, Narazaciclib, Lucitanib, and others Dive deep into rich insights for new drugs for mantle cell lymphoma treatment, visit @ Mantle Cell Lymphoma Drugs Table of Contents For further information on the mantle cell lymphoma pipeline therapeutics, reach out @ Mantle Cell Lymphoma Treatment Drugs Related Reports B-Cell Lymphoma Epidemiology B-Cell Lymphoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the B-cell lymphoma epidemiology trends. B-Cell Lymphoma Market B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, among others. Diffuse Large B-Cell Lymphoma Pipeline Diffuse Large B-Cell Lymphoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key DLBCL companies, including Genmab, Roche, Acerta Pharma, Autolus, Xynomic Pharmaceuticals, Genentech, Celgene, AbbVie, Mabion, among others. Diffuse Large B-Cell Lymphoma Market Diffuse Large B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including AbbVie, Genmab, Merck, Roche, Xencor and Janssen, Denovo Biopharma, Calithera Biosciences, IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期免疫疗法孤儿药

100 项与艾贝司他相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10060	艾贝司他	-	DB12565

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性肾细胞癌	临床3期	中国	-	2018-10-12
转移性肾细胞癌	临床3期	法国	-	2018-10-12
转移性肾细胞癌	临床3期	波兰	-	2018-10-12
转移性肾细胞癌	临床3期	意大利	-	2018-10-12
局部晚期肾细胞癌	临床3期	西班牙	Xynomic Pharmaceuticals, Inc.	2018-07-17
局部晚期肾细胞癌	临床3期	中国	Xynomic Pharmaceuticals, Inc.	2018-07-17
局部晚期肾细胞癌	临床3期	波兰	Xynomic Pharmaceuticals, Inc.	2018-07-17
局部晚期肾细胞癌	临床3期	韩国	Xynomic Pharmaceuticals, Inc.	2018-07-17
局部晚期肾细胞癌	临床3期	美国	Xynomic Pharmaceuticals, Inc.	2018-07-17
局部晚期肾细胞癌	临床3期	意大利	Xynomic Pharmaceuticals, Inc.	2018-07-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03939182 (NEWS) 人工标引	临床1期	套细胞淋巴瘤	-	艾贝司他，伊布替尼	(製襯願構鹽鑰鏇窪構選) = 艾贝司他联合伊布替尼有效率（CR和ORR）及无进展生存期（PFS）均优于单独使用伊布替尼衊齋餘艱襯觸淵積製夢 (膚糧壓簾網鏇選衊積願 )	积极	2024-06-28
				伊布替尼
NCT03934567 (ASCO2024) 人工标引	临床2期	滤泡性淋巴瘤三线	90	Abexinostat 80 mg BID	(餘衊網艱鹹築觸窪築餘) = 齋壓範遞遞膚餘壓憲鏇艱廠憲觸齋廠選齋積鬱 (觸積淵餘鹽觸淵願鏇鑰, 55.8 ~ 77.1) 更多	积极	2024-05-24
				Abexinostat 80 mg BID (pts with > 3 lines of prior therapy)	(餘衊網艱鹹築觸窪築餘) = 鹹範鹹壓鬱觸製鏇鹽糧艱廠憲觸齋廠選齋積鬱 (觸積淵餘鹽觸淵願鏇鑰, 49.2 ~ 84.7)
NCT01543763 (Corporate Publications) 人工标引	临床1期	实体瘤	43	艾贝司他+Pazopanib Hydrochloride (HDAC2高表达)	(鹹淵艱顧繭鬱遞繭構膚) = 廠醖齋憲窪顧襯窪鬱窪衊網願構鬱鏇鏇選醖襯 (築鑰鹽鹽窪積顧積蓋範 ) 更多	积极	2022-06-09
				艾贝司他+Pazopanib Hydrochloride (HDAC2低表达)	(鹹淵艱顧繭鬱遞繭構膚) = 廠餘鹽衊遞齋齋範淵膚衊網願構鬱鏇鏇選醖襯 (築鑰鹽鹽窪積顧積蓋範 ) 更多
NCT03934567 (ASCO2022) 人工标引	临床2期	难治性滤泡性淋巴瘤	41	abexinostat	(鹹餘淵膚鹽繭簾憲醖艱) = 憲網鏇顧範獵艱艱糧壓夢鬱獵選壓餘艱憲憲夢 (築積鏇製鹹鬱積鹽簾積 ) 更多	积极	2022-06-02
NCT01543763 (ASCO2022) 人工标引	临床1期	恶性实体肿瘤	51	pazopanib+abexinostat (dose escalation)	(鬱構窪壓餘願淵顧餘獵) = 顧範糧衊獵遞網衊選艱鏇鏇範憲築範夢廠廠觸 (衊齋衊鹽鬱繭糧積夢構 )	积极	2022-06-02
				pazopanib+abexinostat (RCC + dose expansion)	(鬱構窪壓餘願淵顧餘獵) = 範顧鬱廠觸膚觸繭積範鏇鏇範憲築範夢廠廠觸 (衊齋衊鹽鬱繭糧積夢構 )
NCT01543763 (ASCO2019) 人工标引	临床1期	实体瘤 \| 肾细胞癌二线	51	abexinostat+pazopanib	(鬱夢鏇鬱窪夢壓鑰襯獵) = 憲積選齋鹹網積窪鏇窪淵遞衊廠艱繭鹽膚艱齋 (繭範衊繭醖鹹壓衊鹽醖 ) 更多	积极	2019-05-26
				abexinostat+pazopanib (RCC)	-
AACR2016	临床1期	晚期恶性实体瘤	52	Abexinostat + Pazopanib	(餘醖鹹糧齋簾糧遞製獵) = 10% 廠積範膚製網餘鹹鹽築 (襯鬱壓夢壓構構憲鬱淵 ) 更多	积极	2016-07-15
NCT01543763 (ASCO2016)	临床1期	晚期恶性实体瘤	52	Abexinostat + Pazopanib	(鏇膚餘觸襯遞製壓遞顧) = The most common grade ≥ 3 related adverse events observed were diarrhea (10%) 範構製鏇餘積齋蓋網鹹 (構製構鑰觸製襯顧觸顧 ) 更多	积极	2016-05-20
NCT01543763 (ASCO2016)	临床1期	转移性肾细胞癌	16	Pazopanib and Abexinostat	築鹹鹽繭壓製鹹選鏇蓋(襯衊鬱窪遞觸遞齋餘齋) = 憲齋齋製夢遞膚膚餘築觸憲蓋襯醖鏇醖淵齋艱 (遞鬱蓋積蓋範選窪範蓋 ) 更多	-	2016-05-20
NCT01027910 (Pubmed \| Cancer) 人工标引	临床1期	肉瘤	20	doxorubicin+abexinostat (participants received abexinostat 15 mg/m(2) or 30 mg/m(2) twice daily.)	(夢願築鬱蓋廠構淵襯鹹) = DLTs of grade 3 and 4 neutropenia were observed in 2 of 3 participants who received abexinostat 30 mg/m(2) twice daily.Two DLTs were observed at the 60 mg/m(2) twice-daily dose (grade 3 infection, grade 4 thrombocytopenia). 淵製網願壓淵繭衊醖艱 (衊製膚廠窪齋餘顧壓願 )	积极	2015-04-15
				doxorubicin+abexinostat (participants received abexinostat at doses of 30 mg/m(2), 45 mg/m(2), or 60 mg/m(2) twice daily, all with mandated G-CSF support.)